Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/14155
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | SHKEDY, Ziv | - |
dc.contributor.advisor | VAN SANDEN, Suzy | - |
dc.contributor.author | BIGIRUMURAME, Theophile | - |
dc.date.accessioned | 2012-09-27T10:28:25Z | - |
dc.date.available | 2012-09-27T10:28:25Z | - |
dc.date.issued | 2012 | - |
dc.identifier.uri | http://hdl.handle.net/1942/14155 | - |
dc.description.abstract | In some clinical research, the endpoint of greatest relevance to inferences concerning therapeutic efficacy is frequently not practical or even feasible to measure. Sometimes the determination of the true endpoint is difficult, requiring an expensive, invasive or uncomfortable procedure. In some trials, however, the main endpoint of interest, for example death, is rare and/or takes a long period of time to reach. In such trials, there would be benefit in finding a more proximate endpoint to determine more quickly the effect of an intervention. In this report, a meta-analytic approach was used to validate progression free survival as a surrogate for Overall Survival. Firstly the logarithm of both endpoints were assumed to be normally distributed and fixed effects models were applied to them. Secondly both endpoints were considered as failure time and appropriate methods were applied. In all cases, the individual and trial level surrogacy estimates were too low to be useful. It was | - |
dc.format.mimetype | Application/pdf | - |
dc.language | en | - |
dc.language.iso | en | - |
dc.publisher | tUL Diepenbeek | - |
dc.title | Evaluation of progression free survival as surrogate endpoint for overall survival for prostate cancer treatment | - |
dc.type | Theses and Dissertations | - |
local.format.pages | 0 | - |
local.bibliographicCitation.jcat | T2 | - |
dc.description.notes | Master of Statistics-Biostatistics | - |
local.type.specified | Master thesis | - |
dc.bibliographicCitation.oldjcat | D2 | - |
item.accessRights | Open Access | - |
item.contributor | BIGIRUMURAME, Theophile | - |
item.fulltext | With Fulltext | - |
item.fullcitation | BIGIRUMURAME, Theophile (2012) Evaluation of progression free survival as surrogate endpoint for overall survival for prostate cancer treatment. | - |
Appears in Collections: | Master theses |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10299932011009.pdf | 1.82 MB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.